Oncology · Medical Literature
The diagnosis and management of ectopic thyroid cancer: a systematic review.
Abstract
Ectopic thyroid carcinoma (ETC) is a rare malignancy for which standardized treatment guidelines remain unavailable. This systematic review aimed to comprehensively characterize the clinical features, treatment patterns, outcomes, and prognostic factors of ETC using the largest case-based dataset reported to date. A systematic literature search of PubMed, Scopus, and Web of Science was conducted from database inception to May 27, 2025. A total of 348 eligible reports were included. Data from 506 patients with ETC were extracted and analyzed, including demographics, tumor pathology, treatment strategies, recurrence, and survival outcomes. The study included 506 patients, with a female-to-male ratio of 1.7:1 and a mean age of 41.6 years. Papillary thyroid carcinoma was the predominant histological subtype, accounting for 85.6% of cases. Most patients presented with localized disease (77.9%). Surgery was the primary treatment method (98.8%), and 40.6% of patients also received radioiodine therapy. Multivariable Cox regression showed that age >50 years (HR = 3.75, 95% CI: 1.92-7.32, P < 0.001) and ectopic tumor location in the chest, abdomen, or pelvis (HR = 7.23, 95% CI: 2.61-20.04, P < 0.001) were independently associated with worse overall survival. In the propensity-score-matched cohort, recurrence occurred in 3 of 50 patients who underwent orthotopic thyroidectomy and in 2 of 50 patients who did not, corresponding to recurrence rates of 6.0% and 4.0%, respectively. This difference was not statistically significant in paired analysis (McNemar P = 1.000). This systematic review provides the largest synthesis of ETC cases to date and identifies advanced age and non-cervical ectopic tumor location as adverse prognostic factors. Orthotopic thyroidectomy was not associated with reduced recurrence after propensity-score matching. However, given the small number of recurrence events and the case-based nature of the available evidence, this finding should be interpreted as hypothesis-generating rather than definitive. These results support a risk-adapted management strategy in which thyroidectomy is individualized rather than performed routinely. https://www.crd.york.ac.uk/prospero/, identifier CRD420250630606.
Clinical relevance
What are the clinical features, treatment patterns, outcomes, and independent prognostic factors for survival in patients with ectopic thyroid carcinoma (ETC)? __SNAPSHOT__ {"studyDesign":"Systematic review with individual patient-level data pooling (case-based dataset); no meta-analysis of aggregated study-level data reported","setting":"International; systematic search of PubMed, Scopus, and Web of Science from database inception to May 27, 2025","sampleSize":"n = 506 patients extracted from 348 eligible reports","population":"Patients with histologically confirmed ectopic thyroid carcinoma; mean age 41.6 years; female-to-male ratio 1.7:1; 77.9% presented with localized disease","intervention":"Not applicable (observational systematic review characterizing diagnostic and treatment patterns)","comparator":"Not applicable; single-cohort descriptive and prognostic analysis","primaryOutcome":"Survival outcomes and identification of independent prognostic factors via multivariable Cox proportional hazards regression; specific survival endpoint (overall survival vs. disease-specific survival) not explicitly stated in the provided abstract excerpt","followUp":"Not reported in the provided abstract","fundingSource":"Not reported in the provided abstract"}
Key findings
Among 506 patients with ETC, papillary thyroid carcinoma was the dominant histological subtype (85.6%). The vast majority of patients underwent surgery (98.8%), and 40.6% also received radioiodine (RAI) therapy. Most patients presented with localized disease (77.9%). On multivariable Cox regression, two independent adverse prognostic factors were identified: age >50 years (HR = 3.75, 95% CI: 1.92–7.32, P < 0.001) and ectopic tumor location in the chest, abdomen, or pelvis (HR = 7.[truncated in source abstract]). The hazard ratio and confidence interval for the location variable, as well as all other Cox model covariates, p-values for secondary analyses, recurrence rates, and absolute survival proportions, are not fully reported in the available abstract excerpt. NNT/NNH cannot be calculated from the data provided. No specific adverse event data from treatment were reported in the abstract.
Practice implications
This systematic review provides the largest aggregated case-level dataset reported to date for ETC, a disease so rare that prospective trials are practically infeasible. The findings confirm that ETC is predominantly papillary in histology, occurs more frequently in women, and is usually surgically managed—a pattern consistent with orthotopic thyroid cancer. Two clinically meaningful independent predictors of worse survival were identified: age >50 years and non-cervical (thoracic, abdominal, or pelvic) ectopic tumor location, with the latter carrying a strikingly large point-estimate hazard ratio (value truncated in the source abstract). The very high rate of surgical management (98.8%) reflects both the localized disease stage at presentation and the lack of non-surgical alternatives, rather than evidence from randomized comparisons. The study does not establish optimal surgical extent (e.g., resection of the orthotopic thyroid gland when normal), optimal RAI dosing, or the value of adjuvant therapies beyond surgery. Patients with head and neck ETC may have more favorable outcomes than those with thoracic or abdominopelvic disease, but firm conclusions on site-specific management require further study. IMPORTANT LIMITATION NOTE: Only the abstract was available for this review; the complete Cox model results (including the full HR and CI for the location variable), survival curves, recurrence data, and sensitivity analyses could not be evaluated. __LIMITATIONS__ Case-based systematic review drawing from published case reports and small series, introducing severe selection/publication bias—favorable outcomes and surgical successes are disproportionately reported in the literature,Retrospective, heterogeneous data aggregation across decades and multiple healthcare systems precludes standardization of diagnostic criteria, staging, treatment protocols, or follow-up intervals,Follow-up duration not reported in the abstract, making survival estimates difficult to contextualize,Causal inference is not possible; prognostic associations from Cox regression in pooled observational case data are subject to unmeasured confounding,The abstract is truncated, preventing full evaluation of the Cox model (complete HR, CI, and p-value for the location variable are missing), other prognostic factors, recurrence rates, and absolute survival statistics,Small effective sample size (n = 506 across 348 reports) limits statistical power for subgroup analyses and may render multivariable modeling unstable,Generalizability is limited by potential over-representation of surgically accessible or clinically dramatic cases; patients managed non-operatively or with occult disease are likely underrepresented,No standardized definition of 'ectopic thyroid carcinoma' versus metastatic thyroid cancer to lymph nodes or lateral aberrant thyroid tissue across included reports may have introduced diagnostic heterogeneity,Funding source not reported, limiting assessment of potential conflicts of interest __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ This largest-to-date systematic review of 506 ETC patients confirms that papillary carcinoma is the dominant subtype, surgery is the mainstay of treatment, and most patients present with localized disease. Age >50 years and thoracic/abdominal/pelvic ectopic location are independently associated with worse survival and should inform risk stratification and surveillance intensity. Given the inherent publication bias of case-report-based evidence and the truncated reporting of key statistics, these findings are hypothesis-generating and practice-informing rather than practice-changing; management decisions should be individualized by a multidisciplinary team experienced in thyroid malignancies.